entertainment -WSS

entertainment

author：entertainment 2025-10-01 11:34:53 - browse：96595

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year.

The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was 54.9%, 51.3%, and 51.0% from the lowest to highest doses.

When compared with the 29.7% of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Why getting cancer drugs just got harder for rural patients

hotspot

WSS

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Kenai launches with $82 million for Parkinson’s stem cell therapy

House looks to weaken Medicare negotiation

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Biotech companies concerned about China biosecurity crackdown

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare proposal to cover medical devices draws a mixed reaction

HIV drugs protect against transmission, even in unprotected sex

Trump demands the U.S. pay no more for drugs than other countries … again

RaDonda Vaught to speak at CommonSpirit event on patient safety

As demand for Covid shots wanes, Moderna seeks its next success

How to address the problem of discarded donor organs

Psychedelics group wrestles with new pharma identity

Congress gives doctors Medicare pay bump

At least 13 dead in Texas as scorching temps continue

Kenai launches with $82 million for Parkinson’s stem cell therapy

Wikipedia

Covid isolation guidance eased by the CDC

HIV drugs protect against transmission, even in unprotected sex

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Flu vaccine offering decent levels of protection this winter, new data show

Change Healthcare cyberattack outage could last weeks

The Pandemic Treaty must support building strong health systems

leisure time

hotspot

hotspot

leisure time